| Symbol | XBIO |
|---|---|
| Name | XENETIC BIOSCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 945 CONCORD STREET, FRAMINGHAM, Massachusetts, 01701, United States |
| Telephone | +1 781 - 778-7720 |
| Fax | — |
| — | |
| Website | https://www.xeneticbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001534525 |
| Description | Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patients malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Additional info from NASDAQ: |
(99% Positive) XENETIC BIOSCIENCES, INC. (XBIO) Announces Business Combination
Read moreXenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Read moreXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Read moreXenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Read moreNew Form SCHEDULE 13G - Xenetic Biosciences, Inc. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0002103370-26-000001 <b>Size:</b> 42 KB
Read moreNew Form SCHEDULE 13G/A - Xenetic Biosciences, Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001037389-26-000042 <b>Size:</b> 9 KB
Read more(99% Positive) XENETIC BIOSCIENCES, INC. (XBIO) Announces Business Combination
Read moreXenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Read more(99% Neutral) XENETIC BIOSCIENCES, INC. (XBIO) Announces New Board Appointment
Read moreNew Form 10-K/A - Xenetic Biosciences, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001683168-26-003207 <b>Size:</b> 716 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03077698 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial … | Phase2 | Endometrial Cancer | Terminated | 2017-06-14 | 2020-07-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| progestin therapy | Drug | Phase PHASE2 | Endometrial Cancer | TERMINATED | NCT03077698 |
| Sodium Cridanimod | Other | Phase PHASE2 | Endometrial Cancer | TERMINATED | NCT03077698 |
| progestin therapy | DRUG | Phase PHASE2 | Endometrial Cancer | TERMINATED | NCT03077698 |
| Sodium Cridanimod | DRUG | Phase PHASE2 | Endometrial Cancer | TERMINATED | NCT03077698 |